/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Company Overview CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. We deliver solutions designed to empower clinicians and improve patient outcomes.
$49.27
$0.33 (-0.67%)
Live · 07:17 PM
The business is unprofitable at the operating level (-8.10% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 13.8%, still solid. Margins contracted 20.3pp, which offsets some of the top-line progress.
ROIC dropped from 11.52% to -6.61%, capital efficiency is deteriorating. Operating margin contracted 20.3pp YoY, cost discipline may be slipping.
23.8x earnings. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$458M
▲ +13.8% YoY
Net Income (TTM)
$111M
▼ -140.6% YoY
Op. Margin
23.61%
▼ -20.3pp YoY
ROIC
28.66%
▼ -18.1pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$94M
▲ +10.5% YoY
Net Debt
-$354M
Net Cash Position
Cash & Equiv.
$374M
5Y CAGR: +14.6%
Continue Research
SourceComputed from the 10-Q filed 30 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 31 Jul 2026. How this is calculated.
Price from market data, live as of 3 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 23.8, CareDx (CDNA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, CareDx scores 60/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
CareDx scores 60 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 23.6% operating margin and a 28.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CDNA's valuation and scores 60/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.